Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications

Adv Med Sci. 2023 Sep 25;68(2):359-365. doi: 10.1016/j.advms.2023.09.008. Online ahead of print.ABSTRACTProstate cancer (PC) is the second most common cancer in men worldwide. Homologous recombination repair (HRR) gene defects have been identified in a significant proportion of metastatic castration-resistant PC (mCRPC) and are associated with an increased risk of PC and more aggressive PC. Importantly, it has been well-documented that poly ADP-ribose polymerase (PARP) inhibition in cells with HR deficiency (HRD) can cause cell death. This has been exploited for the targeted treatment of PC patients with HRD by PARP inhibitors. Moreover, it has been shown that platinum-based chemotherapy is more effective in mCRPC patients with HRR gene alterations. This review highlights the prognosis and therapeutic implications of HRR gene alterations in PC.PMID:37757663 | DOI:10.1016/j.advms.2023.09.008
Source: Advances in Medical Sciences - Category: Biomedical Science Authors: Source Type: research